Biocartis
- Accelerated bookbuild offering amounting to €32.7m.
- Proceeds will be used to finance further clinical trials, to support the global roll-out of its products and to fund the expansion of manufacturing capacity.
- Kempen & Co acted as Joint Bookrunner in the transaction.
